Skip to content

Effect of Soleus Muscle Kinetic Control Training on Gait and Electromyographic Activity in Patients With Stroke

Effect of Soleus Muscle Kinetic Control Training on Gait and Electromyographic Activity in Patients With Stroke

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07309081
Acronym
EMG
Enrollment
40
Registered
2025-12-30
Start date
2025-12-15
Completion date
2026-06-15
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

kinetic control, gait, EMG, stroke

Brief summary

this study was designed to investigate the effect of soleus muscle kinetic control training on Gait and electromyographic activity of the calf muscle in patients with stroke

Detailed description

Stroke is a neurological condition characterized by a reduced blood supply to the brain tissue, resulting in paralysis of part or all of the body, limiting physical activity and social participation. Gait impairment accounts for the largest proportion of physical activity limitations in stroke patients and is characterized by muscle weakness, foot drop, spasticity, and foot deformity .Gait abnormalities following stroke are often disabling. Reduced ankle dorsiflexion, knee flexion, or hip flexion torques are often postulated causes of compromised toe clearing during the swing phase of gait. conversely, gait asymmetry and reduced walking speed has been attributed to weakness of the planter flexors.The kinetic control comprises balanced presentation of the movement choices with ideal interaction among the key components for the sensorimotor neuromuscular control that mediated by afferent sensory input, particularly the proprioceptive input, CNS integration, optimal motor co-ordination, and physiological stresses to assure functional dynamic stability and controlled mobility. forty patients with stroke will be assigned to two groups; one group will recieve kinetic control plus conventional therapy and control group will receive conventinoal therapy alone.

Interventions

OTHERsoleus kinetic control

patients will receive kinetic control for 30 minutes structural progressive training for the soleus muscle guided by the EMG biofeedback plus conventional therapy; 1)Start in crook lying position with the heels level with the pelvis and lift the pelvis clear of the floor followed by bilateral heel raise,2)Progress further by shifting weight onto one leg and holding the heel raise and slowly lowering eccentrically on 1 foot, the next progression is to perform the same movement with the heels lower than the pelvis on step -below the pelvis. The exercise graduation will be guided by the visual EMG Biofeedback participants will receive feedback on soleus activation throughout the training.

OTHERconventional therapy

the patients will receives conventional physiotherapy program static stretching and stretching board for calf muscle, stretching board, and push off exercises by having the patient push against the therapist or a treatment table during forward gait ( 30 minute), static stretch(30sec\\set , rest 20sec\\set total 5 set, 3 times \\week , for 8 week ), stretching board (4 min\\set , rest 1 min\\set total 2 set , 3 times \\week , for 8 week ) (10 minute) push off training (15 minute 3 times \\week , for 8 week )x2

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

opaque sealed envelope

Intervention model description

kinetic and traditional therapy

Eligibility

Sex/Gender
ALL
Age
45 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Ischemic or hemorrhagic stroke, as confirmed by CT and or MRI scan. * Age of the patients between 45 to 60 years old. * Ability to walk a minimum of 10 m with or without some physical assistance from a therapist (functional ambulation category more than 2). * Demonstrate weakness of the foot muscles, measured by muscle function tests according Medical Research council scale more than 3. * Muscle tone of the affected lower limb ranges from 1 to +1 according to modified Ashworth scale.

Exclusion criteria

* Unilateral neglect, hemianopia, or apraxia * Having any other neurological disorder affecting their lower extremities e.g. MS, Parkinsonism, peripheral neuropathy. * Patients with previous fractures in lower limb (Ankle or foot). * Patients with musculoskeletal disorder such as severe arthritis, ankle surgery, leg length discrepancy or contractures of fixed deformity of ankle joint. * Patients with visual, auditory impairment affecting their ability to complete tasks. * Patients with cognitive impairments

Design outcomes

Primary

MeasureTime frameDescription
muscle amplitudeup to eight weeksA steady device will be used to assess muscle amplitude in the form of RMS with microvolt as the measurement unit
giat functionup to eight weeksThe Dynamic Gait Index (DGI) is an ordinal test of gait function evaluates the capacity to adapt gait to complex walking tasks encountered in everyday life. Eight aspects of gait are scored based on observation as the patient walks over a 6.1-m level surface. The rater records an ordinal score that ranges from 0 (unable or done very poorly) to 3 (normal score) for a total point value of 24. Scores of less than 21 appear to suggest risk for falls
Gait Cycle timeup to eight weekstime of gait cycle (seconds) will be measured by steady device
step timeup to eight weeksthe time of step by seconds will be measured by steady device
cadenceup to eight weeksCadence, number of steps per minute, will be measured by steady device
stance phase percentageup to eight weeksthe percentage of stance phase will be measured by steady device
swing phase percentageup to eight weeksthe percentage of swing phase will be measured by steady device
single and double support percentageup to eight weekssingle and double support percentage of gait cycle will be measured by steady device
first and second double support percentageup to eight weeksfirst and second double support percentage of gait cycle will be measured by steady devcie
stride lengthup to eight weeksstride length by cm will be measured by steady device
gait speedup to eight weeksgait speed by km/h will measured by steady device

Contacts

Primary Contacthabiba mohamed, master
dochabiba4@gmail.com0 10 90708377

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026